LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

N. Reinmuth, M. Özgüroğlu, N.B. Leighl, D. Galetta, I. Hacibekiroglu, J. Roubec, M.A.N. Sendur, E. Bria, I. Cicin, C. Grohé, H. Harputluoglu, S. Kilickap,S. Novello, P. Opalka, F. Riccardi, R.K. Ruseva, S. Lang, M. Hodari, N. Donner,F. de Marinis

Immuno-Oncology and Technology（2023）

引用 0|浏览1